May 12
|
Cellectis Reports Financial Results for the First Quarter 2025
|
May 6
|
Cellectis to Report First Quarter Financial Results on May 12, 2025
|
Apr 25
|
3 European Penny Stocks With At Least €100M Market Cap
|
Apr 21
|
Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
|
Mar 13
|
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
|
Feb 24
|
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
|
Dec 29
|
Analysts Predict 400% Upside Potential for This Penny Stock
|
Aug 26
|
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
|
Aug 7
|
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
|
Aug 6
|
Cellectis Provides Financial Results for the Second Quarter 2024
|
Jul 25
|
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
|
Jun 12
|
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
|
May 7
|
AstraZeneca concludes equity investment in Cellectis
|
May 6
|
AstraZeneca ups stake in Cellectis in latest cell therapy bet
|
May 6
|
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
|
May 2
|
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
|
Apr 29
|
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
|
Apr 22
|
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
|
Apr 10
|
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
|
Apr 8
|
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
|